This was discussed several times here and a lot of people posted even medical articles and proof that CGM is not going to disappear. It would have by now if it was that easy. There were several attempts by industry giants and you still see even PE firms trying to invest in the CGM.
This company has so many balls in the air, even one or two of them can change the picture dramatically. I liked the reference to January PR and sticking to the timelines in the last PRs. Giant in the room is the private label for the short run and GenPrecis partnerships in the medium run. I am hoping to see something tangible on the private label by this AR or by the Q1 release.